Cannabis company Aphria recently signed a similar deal for an oral film delivery method

CURE Pharmaceuticals has created an oral film that delivers cannabis extracts and biosynthetic cannabinoids

Canopy Growth Corp (TSX:WEED, NYSE:CGC) is inking deals left and right ahead of the impending legalization in Canada this October.

The cannabis producer signed a deal for rights to ’s (OTCQB:CURR) CUREfilm technology, a thin oral film that delivers cannabis extracts and biosynthetic cannabinoids.

CURE will retain the rights to manufacture biosynthetic cannabinoids for pharmaceutical use.

Shares of CURE Pharmaceutical surged more than 35% to US$3.90 in Thursday afternoon trading while shares of Canopy Growth were down nearly 6% to US$49.20.

The pharmaceutical company’s press release did not specify the cannabis company but a company spokesperson confirmed the deal is with Canopy Growth.

“At CURE, we focus on synthetic cannabinoids for CUREfilm products, but with our new licensing business model, we will expand the impact and applications of our technology to these other promising approaches by partnering with an industry leader in this market,” said CEO Rob Davidson in the company’s press release.

Inc (TSX:APH, OTCQB:APHQF) recently entered into a similar non-binding agreement with biotech Rapid Dose Therapeutics Inc for the rights to its QuickStrip products, another version of a fast-dissolving oral strip.

Canopy Growth has entered a handful of agreements this week, including a supplier deal with Corporation ( ). The company will be the preferred supplier of medical cannabis to the seniors in ’s long-term care and retirement homes.

The cannabis company also recently closed its acquisition of Hiku Brands Ltd, a craft cannabis producer and retailer.

--Updated to include confirmation from CURE Pharmaceutical spokesperson and recent share price